A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets the immune checkpoint B7-H3 for diffuse intrinsic pontine glioma, or DIPG, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback